Beijing Mabworks Biotech Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2003)

Organization Overview

First Clinical Trial
2017
NCT04103905
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Beijing Mabworks Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (5)

bevacizumab (avastin) (1 trial)

cyclosporine (sandimmune) (2 trials)

lenalidomide (revlimid) (2 trials)

mil62 (4 trials)

rituximab (rituxan) (3 trials)

Drugs in Phase 2 Trials (1)

mbs303 (1 trial)

Drugs in Phase 1 Trials (4)

mbs301 (1 trial)

mil93 (1 trial)

mil95 (1 trial)

mil97 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 10